Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic

NCT04975061 is registered in ClinicalTrials.gov with Shanghai YingLi Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT04975061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04975061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase
Observational
Overall status
Unknown status
Start date
August 1, 2021
Completion date
December 30, 2022
Enrollment
58 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

effectiveness，safety，thymic cancer